Total Payments
$3.6M
2024 Payments
$274,352
Companies
33
Transactions
2,588
Medicare Patients
1,429
Medicare Billing
$142,980
Payment Breakdown by Category
Other$2.2M (60.4%)
Consulting$772,672 (21.5%)
Travel$353,632 (9.9%)
Research$247,723 (6.9%)
Food & Beverage$45,545 (1.3%)
Education$1,977 (0.1%)
Gifts$15.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.1M | 698 | 58.6% |
| Consulting Fee | $772,672 | 132 | 21.5% |
| Travel and Lodging | $353,632 | 815 | 9.9% |
| Unspecified | $247,723 | 55 | 6.9% |
| Honoraria | $56,675 | 22 | 1.6% |
| Food and Beverage | $45,545 | 834 | 1.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,000 | 1 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,595 | 1 | 0.1% |
| Education | $1,977 | 29 | 0.1% |
| Gift | $15.00 | 1 | 0.0% |
Payments by Type
General
$3.3M
2,533 transactions
Research
$247,723
55 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $928,947 | 675 | $0 (2024) |
| Biogen, Inc. | $757,149 | 413 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $437,833 | 303 | $0 (2024) |
| EMD Serono, Inc. | $277,470 | 250 | $0 (2024) |
| Genentech USA, Inc. | $240,038 | 168 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $183,522 | 111 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $169,687 | 164 | $0 (2024) |
| Celgene Corporation | $163,093 | 151 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $132,422 | 25 | $0 (2019) |
| TG Therapeutics, Inc. | $87,961 | 66 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $274,352 | 178 | Alexion Pharmaceuticals, Inc. ($83,868) |
| 2023 | $345,003 | 228 | Alexion Pharmaceuticals, Inc. ($106,147) |
| 2022 | $401,007 | 223 | Biogen, Inc. ($113,820) |
| 2021 | $241,929 | 129 | Biogen, Inc. ($99,861) |
| 2020 | $341,587 | 223 | Biogen, Inc. ($95,584) |
| 2019 | $843,510 | 553 | GENZYME CORPORATION ($308,616) |
| 2018 | $572,490 | 558 | GENZYME CORPORATION ($218,806) |
| 2017 | $568,536 | 496 | GENZYME CORPORATION ($234,208) |
All Payment Transactions
2,588 individual payment records from CMS Open Payments — Page 1 of 104
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Celgene Corporation | ZEPOSIA (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Neuroscience | ||||||
| 12/17/2024 | GENZYME CORPORATION | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $6.00 | General |
| Category: Neurology | ||||||
| 12/10/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Neurology | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $597.08 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $212.19 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $31.39 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/03/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,555.00 | General |
| Category: Neurology | ||||||
| 12/03/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $375.00 | General |
| Category: Neurology | ||||||
| 12/03/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $160.00 | General |
| Category: Neurology | ||||||
| 12/03/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | Cash or cash equivalent | $31.19 | General |
| Category: Neurology | ||||||
| 12/03/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $10.38 | General |
| Category: Neuroscience | ||||||
| 11/21/2024 | GENZYME CORPORATION | AUBAGIO (Drug) | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: Neurology | ||||||
| 11/19/2024 | Genentech, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $104.56 | General |
| Category: Immunology | ||||||
| 11/15/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,795.00 | General |
| Category: Neurology | ||||||
| 11/15/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,795.00 | General |
| Category: Neurology | ||||||
| 11/12/2024 | UCB, Inc. | Rystiggo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,680.00 | General |
| Category: Neurology | ||||||
| 11/12/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $930.00 | General |
| Category: Immunology | ||||||
| 10/31/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,175.00 | General |
| Category: Neurology | ||||||
| 10/31/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Travel and Lodging | Cash or cash equivalent | $645.24 | General |
| Category: Neurology | ||||||
| 10/30/2024 | UCB, Inc. | Rystiggo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Real-world experience of using Tysabri in 750 MS patients over 15 years in a single US center in the absence of PML - focusing on unique clinical practice in evolution of risk mitigating strategies. | Biogen, Inc. | $207,425 | 3 |
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $8,725 | 2 |
| PRO-MS: A Prospective, Noninterventional Trial to Evaluate Patient-Reported Outcomes in MS Patients Treated with Alemtuzumab (LEMTRADA) In Routine Clinical Practice | GENZYME CORPORATION | $8,498 | 5 |
| A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis ( | GENZYME CORPORATION | $4,713 | 9 |
| TeriPRO | GENZYME CORPORATION | $3,351 | 8 |
| TERI-PRO: A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple S | GENZYME CORPORATION | $2,412 | 4 |
| Teri-PRO (Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients) | SANOFI-AVENTIS U.S. LLC | $2,191 | 2 |
| An Extension Protocol for Multiple Scerlosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $1,769 | 2 |
| TERI-PRO: A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple | SANOFI-AVENTIS U.S. LLC | $1,624 | 5 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of | GENZYME CORPORATION | $1,603 | 3 |
| TeriPRO -A prospective, single-arm, clinical-setting study to describe efficacy, tolerability and convenience of Terifluomide treatment using Patient Reported Outcomes (PROs) in Relapsing Multiple Scl | GENZYME CORPORATION | $1,094 | 2 |
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) | GENZYME CORPORATION | $908.94 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficiacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of | GENZYME CORPORATION | $804.00 | 1 |
| TERI-PRO A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sc | GENZYME CORPORATION | $730.91 | 1 |
| Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis with Relapses | GENZYME CORPORATION | $618.46 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of | SANOFI-AVENTIS U.S. LLC | $545.14 | 2 |
| Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (TERI-PRO) | SANOFI-AVENTIS U.S. LLC | $250.50 | 1 |
| TeriPROA Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Scl | GENZYME CORPORATION | $246.84 | 1 |
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study | GENZYME CORPORATION | $213.06 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 177 | 289 | $138,681 | $17,066 |
| 2022 | 6 | 313 | 684 | $329,250 | $35,559 |
| 2021 | 6 | 383 | 598 | $274,862 | $39,757 |
| 2020 | 7 | 556 | 1,074 | $412,305 | $50,598 |
Total Patients
1,429
Total Services
2,645
Medicare Billing
$142,980
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 36514 | Mechanical separation of plasma from blood | Facility | 2023 | 26 | 111 | $101,343 | $6,874 | 6.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 89 | 111 | $18,093 | $5,084 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 39 | 44 | $9,108 | $2,930 | 32.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 23 | 23 | $10,137 | $2,178 | 21.5% |
| 36514 | Mechanical separation of plasma from blood | Facility | 2022 | 34 | 239 | $218,207 | $15,218 | 7.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 134 | 182 | $37,936 | $11,176 | 29.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 92 | 114 | $18,582 | $4,841 | 26.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 24 | 24 | $8,251 | $2,004 | 24.3% |
| 36140 | Insertion of needle or tube into artery of arm or leg | Facility | 2022 | 15 | 64 | $43,712 | $1,764 | 4.0% |
| 76937 | Ultrasonic guidance for blood vessel access | Facility | 2022 | 14 | 61 | $2,562 | $555.67 | 21.7% |
| 36514 | Mechanical separation of plasma from opening blood | Facility | 2021 | 34 | 225 | $205,425 | $15,417 | 7.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 109 | 119 | $24,633 | $8,629 | 35.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 99 | 110 | $17,930 | $5,380 | 30.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 72 | 74 | $12,580 | $5,252 | 41.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 28 | 28 | $9,464 | $2,834 | 29.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 41 | 42 | $4,830 | $2,246 | 46.5% |
| 36514 | Mechanical separation of plasma from opening blood | Facility | 2020 | 43 | 255 | $232,815 | $18,265 | 7.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 208 | 335 | $54,605 | $11,749 | 21.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 128 | 148 | $30,636 | $7,826 | 25.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 82 | 85 | $9,775 | $4,661 | 47.7% |
| 36140 | Insertion of needle or catheter into an artery of arm or leg | Facility | 2020 | 19 | 99 | $67,617 | $3,295 | 4.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 24 | 24 | $8,112 | $2,293 | 28.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 20 | 20 | $3,260 | $1,058 | 32.5% |
| 76937 | Ultrasound guidance for accessing into blood vessel | Facility | 2020 | 19 | 95 | $3,990 | $974.03 | 24.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 13 | 13 | $1,495 | $476.56 | 31.9% |
About Dr. Bhupendra Khatri, M.D
Dr. Bhupendra Khatri, M.D is a Neurology healthcare provider based in Milwaukee, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013982594.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bhupendra Khatri, M.D has received a total of $3.6M in payments from pharmaceutical and medical device companies, with $274,352 received in 2024. These payments were reported across 2,588 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.1M).
As a Medicare-enrolled provider, Khatri has provided services to 1,429 Medicare beneficiaries, totaling 2,645 services with total Medicare billing of $142,980. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Milwaukee, WI
- Active Since 02/20/2006
- Last Updated 10/31/2018
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1013982594
Products in Payments
- LEMTRADA (Drug) $452,739
- AUBAGIO (Drug) $385,378
- TYSABRI (Biological) $359,474
- ZEPOSIA (Drug) $263,948
- ULTOMIRIS (Biological) $169,232
- OCREVUS (Biological) $164,266
- Mavenclad (Drug) $141,321
- GILENYA (Drug) $121,257
- Tysabri (Biological) $97,444
- NO PRODUCT DISCUSSED (Drug) $94,626
- ZINBRYTA (Biological) $91,868
- SOLIRIS (Drug) $84,747
- BRIUMVI (Drug) $82,804
- COPAXONE (Drug) $69,977
- TECFIDERA (Drug) $65,251
- Ozanimod (Drug) $64,608
- UPLIZNA (Drug) $61,185
- Soliris (Drug) $57,230
- Rebif (Biological) $46,352
- Ocrevus (Biological) $40,519
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Milwaukee
Staley Brod, M.d, M.D
Neurology — Payments: $1.4M
Neurology $1.4M
Joseph Burgarino, M.d, M.D
Neurology — Payments: $143,112
Neurology $143,112
Sam Hooshmand
Neurology — Payments: $97,704
Neurology $97,704
Fallon Schloemer, D.o, D.O
Neurology — Payments: $48,507
Neurology $48,507
Ryan Brennan, D.o, D.O
Neurology — Payments: $27,544
Neurology $27,544
George Morris, Md, MD
Neurology — Payments: $20,214
Neurology $20,214